Login to Your Account



Clinic Roundup


Friday, February 1, 2013
• Arteriocyte Inc., of Cleveland, said it received FDA approval to start a Phase I trial testing its Magellan System technology in the treatment of thermal burn wounds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription